NPF Fellows Symposium

Article

We are pleased to open the application period for our annual Fellows Symposium.

We are pleased to open the application period for our annual Fellows Symposium.

CME credits and travel scholarships are available to physicians and PhD-level scientists who have demonstrated an interest in pancreatic disease.

The application and other information is available here: http://pancreasfoundation.org/pancreas-community/medical-community/fellows-symposium/

Recent Videos
Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC in an interview with oncology nursing news
Anne M. Reb, PhD, NP, discussing a nurse-led intervention for fear of cancer recurrence.
Ann H. Partridge, MD, MPH, in an interview with Oncology Nursing News at 2024 ESMO Congress.
Elizabeth Burton in an interview with Oncology Nursing News
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
CAR T-Cell Therapy

Novel Bicistronic CAR T-Cell Therapy Induces Durable Responses in Pediatric R/R B-ALL

Courtney Flaherty
December 7th 2024
Article

Treatment with bicistronic CD19/CD22-directed CAR T-cell therapy appeared safe and effective with high remission rates among children with relapsed/refractory B-ALL.

The Vitals

What New Cancer Drugs Were Approved in 2023?

Lindsay Fischer
January 1st 2024
Podcast

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

FDA

FDA Accepts Glofitamab’s sBLA To Treat Relapsed/Refractory DLBCL

Tim Cortese
December 6th 2024
Article

The FDA set a PDUFA date for glofitamab in relapsed or refractory diffuse large B-cell lymphoma for July 20, 2025.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Head and Neck Cancer

NCCN Updates Guidelines for Preferred Frontline Regimen for Advanced Nasopharyngeal Carcinoma

Chris Ryan
December 5th 2024
Article

The NCCN Guidelines Version 1.2025 for Cancer of the Nasopharynx listed toripalimab plus chemotherapy as the standalone preferred regimen in the frontline treatment of patients with advanced nasopharyngeal carcinoma.

Cervical Cancer

Addition of Cadonilimab Improves Survival in Advanced Cervical Cancer

Ashling Wahner
December 5th 2024
Article

Cadonilimab plus platinum-based chemotherapy improved progression-free and overall survival in advanced cervical cancer compared to placebo, showing significant clinical benefits.

© 2024 MJH Life Sciences

All rights reserved.